FDPS, farnesyl diphosphate synthase, 2224

N. diseases: 83; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE To date, the mechanistic, functional, and clinical significance of FDPS in cancer remains unexplored. 30914801 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE To date, the mechanistic, functional, and clinical significance of FDPS in cancer remains unexplored. 30914801 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 AlteredExpression group BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 AlteredExpression group BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE With the effort to develop a more refined map of the connectivity between signal transduction pathways and metabolic networks in cancer FDPS as a new candidate metabolic oncogene in glioblastoma, might suggest to further target MVA pathway as valid therapeutic tool. 29075041 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE With the effort to develop a more refined map of the connectivity between signal transduction pathways and metabolic networks in cancer FDPS as a new candidate metabolic oncogene in glioblastoma, might suggest to further target MVA pathway as valid therapeutic tool. 29075041 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 GeneticVariation group BEFREE Sixteen genes have been associated with cancer, with five specifically associated with prostate cancer (BTG2, IGFBP3, SIRT1, MXI1, and FDPS). 24713434 2014
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 GeneticVariation group BEFREE Sixteen genes have been associated with cancer, with five specifically associated with prostate cancer (BTG2, IGFBP3, SIRT1, MXI1, and FDPS). 24713434 2014
CUI: C0030193
Disease: Pain
Pain
0.040 Biomarker phenotype BEFREE When considered in light of research from other non-English-speaking samples indicating significant psychometric weaknesses for the NRS-11 and VAS and relative strengths of the FPS-R in some groups, the findings suggest that the FPS-R might be the most appropriate pain intensity scale to use when comparisons across populations from different countries is a goal. 30877801 2019
CUI: C0030193
Disease: Pain
Pain
0.040 Biomarker phenotype BEFREE The scores best representing categories of pain for the FPS-R were as follows: no pain, 0 and 2; mild pain, 4; moderate pain, 6; and severe pain, 8 and 10. 27228146 2018
CUI: C0030193
Disease: Pain
Pain
0.040 Biomarker phenotype BEFREE The correlation coefficient between the FPS-R and the Pain Block scale was 0.82 for all participants which increased with age. 29252910 2018
CUI: C0030193
Disease: Pain
Pain
0.040 Biomarker phenotype BEFREE Facial Pain Scale Revised (FPS-R) and Face, Leg, Activity, Cry, Consolability (FLACC) scores were used to evaluate pain and anxiety before, during and after procedure. 28190665 2017
CUI: C0184567
Disease: Acute onset pain
Acute onset pain
0.030 Biomarker phenotype BEFREE Based on available evidence, the NRS-11, FPS-R, and CAS were strongly recommended for self-report of acute pain. 30180088 2019
CUI: C0184567
Disease: Acute onset pain
Acute onset pain
0.030 Biomarker phenotype BEFREE There was poor agreement between caregivers and children when using the WBF and FPS-R for assessment of acute pain in the ED. 31335787 2019
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.030 Biomarker disease BEFREE In silico analysis revealed that FDPS is associated with increasing Gleason score, PTEN functionally deficient status, and poor survival of PCa. 30914801 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.030 Biomarker disease BEFREE In silico analysis revealed that FDPS is associated with increasing Gleason score, PTEN functionally deficient status, and poor survival of PCa. 30914801 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0184567
Disease: Acute onset pain
Acute onset pain
0.030 Biomarker phenotype BEFREE We defined pain scores for the FPS-R and CAS associated with categories of pain intensity in children with acute pain that are generalizable across subgroups based on patient characteristics. 27228146 2018
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma
0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma
0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.030 Biomarker disease BEFREE With the effort to develop a more refined map of the connectivity between signal transduction pathways and metabolic networks in cancer FDPS as a new candidate metabolic oncogene in glioblastoma, might suggest to further target MVA pathway as valid therapeutic tool. 29075041 2017
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma
0.030 Biomarker disease BEFREE With the effort to develop a more refined map of the connectivity between signal transduction pathways and metabolic networks in cancer FDPS as a new candidate metabolic oncogene in glioblastoma, might suggest to further target MVA pathway as valid therapeutic tool. 29075041 2017
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma
0.030 Biomarker disease BEFREE With the effort to develop a more refined map of the connectivity between signal transduction pathways and metabolic networks in cancer FDPS as a new candidate metabolic oncogene in glioblastoma, might suggest to further target MVA pathway as valid therapeutic tool. 29075041 2017
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.030 Biomarker disease BEFREE With the effort to develop a more refined map of the connectivity between signal transduction pathways and metabolic networks in cancer FDPS as a new candidate metabolic oncogene in glioblastoma, might suggest to further target MVA pathway as valid therapeutic tool. 29075041 2017